Nine biomarkers were assessed: (1) the total number of CD8 TILs per mm2, (2) the percentage intra-tumoral (IT) CD8 T cells of total CD8 TILs, (3) the number of PD-1T TILs per mm2 (4) the CD3-positive area per mm2 to estimate the presence of CD3 TILs (5) the CD20-positive area per mm2 to estimate the presence of B cells (6) the number of TLS and (7) the combined number of TLS and LA (referred as TLS+LA) per mm2, (8) the PD-L1 Tumor Proportion Score (TPS) and (9) the TIS score (NanoString) (Fig 1). This evidence concerns the gene CD8A and neoplasm.